

Global Targeted Drugs for Multiple Myeloma Market Growth (Status and Outlook) 2023-2029

https://marketpublishers.com/r/G444DD763F1EN.html

Date: March 2023

Pages: 123

Price: US\$ 3,660.00 (Single User License)

ID: G444DD763F1EN

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

LPI (LP Information)' newest research report, the "Targeted Drugs for Multiple Myeloma Industry Forecast" looks at past sales and reviews total world Targeted Drugs for Multiple Myeloma sales in 2022, providing a comprehensive analysis by region and market sector of projected Targeted Drugs for Multiple Myeloma sales for 2023 through 2029. With Targeted Drugs for Multiple Myeloma sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Targeted Drugs for Multiple Myeloma industry.

This Insight Report provides a comprehensive analysis of the global Targeted Drugs for Multiple Myeloma landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Targeted Drugs for Multiple Myeloma portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Targeted Drugs for Multiple Myeloma market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Targeted Drugs for Multiple Myeloma and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Targeted Drugs for Multiple Myeloma.



The global Targeted Drugs for Multiple Myeloma market size is projected to grow from US\$ million in 2022 to US\$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

United States market for Targeted Drugs for Multiple Myeloma is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Targeted Drugs for Multiple Myeloma is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Targeted Drugs for Multiple Myeloma is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Targeted Drugs for Multiple Myeloma players cover Celgene, Exova, Natco Pharma, Intas Pharmaceuticals, Indiabulls Pharmaceutical, Cipla, Glenmark Pharmaceuticals, Dr Reddy's Laboratories and Qilu Pharmaceutical, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

This report presents a comprehensive overview, market shares, and growth opportunities of Targeted Drugs for Multiple Myeloma market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type

Immunomodulator

Proteasome Inhibitors

Histone Deacetylase Inhibitors (HDACI)

Monoclonal Antibody


Other

Segmentation by application



	Hospital			
	Drug C	Center		
	Clinic			
	Other			
This report also splits the market by region:				
	Americ	cas		
		United States		
		Canada		
		Mexico		
		Brazil		
	APAC			
		China		
		Japan		
		Korea		
		Southeast Asia		
		India		
		Australia		
	Europe	Э		
		Germany		







Dr Reddy's Laboratories
Qilu Pharmaceutical
Chia Tai-Tianqing
Hanson Pharm
Meidakang Huakang Pharmaceutical
Shandong Kongfu Pharmaceutical
J&J
Takeda
Amgen
Bristol Myers Squibb
Abbvie
Seattle Genetics
Karyopharm Therapeutics
PDL BioPharma
Roche
Sumitomo
Merck
Biogen
Schering-Plough
Glaxo



Chiron



Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

- 2.1 World Market Overview
 - 2.1.1 Global Targeted Drugs for Multiple Myeloma Market Size 2018-2029
- 2.1.2 Targeted Drugs for Multiple Myeloma Market Size CAGR by Region 2018 VS 2022 VS 2029
- 2.2 Targeted Drugs for Multiple Myeloma Segment by Type
 - 2.2.1 Immunomodulator
 - 2.2.2 Proteasome Inhibitors
 - 2.2.3 Histone Deacetylase Inhibitors (HDACI)
 - 2.2.4 Monoclonal Antibody
 - 2.2.5 Other
- 2.3 Targeted Drugs for Multiple Myeloma Market Size by Type
- 2.3.1 Targeted Drugs for Multiple Myeloma Market Size CAGR by Type (2018 VS 2022 VS 2029)
- 2.3.2 Global Targeted Drugs for Multiple Myeloma Market Size Market Share by Type (2018-2023)
- 2.4 Targeted Drugs for Multiple Myeloma Segment by Application
 - 2.4.1 Hospital
 - 2.4.2 Drug Center
 - 2.4.3 Clinic
 - 2.4.4 Other
- 2.5 Targeted Drugs for Multiple Myeloma Market Size by Application
- 2.5.1 Targeted Drugs for Multiple Myeloma Market Size CAGR by Application (2018 VS 2022 VS 2029)
 - 2.5.2 Global Targeted Drugs for Multiple Myeloma Market Size Market Share by



Application (2018-2023)

3 TARGETED DRUGS FOR MULTIPLE MYELOMA MARKET SIZE BY PLAYER

- 3.1 Targeted Drugs for Multiple Myeloma Market Size Market Share by Players
- 3.1.1 Global Targeted Drugs for Multiple Myeloma Revenue by Players (2018-2023)
- 3.1.2 Global Targeted Drugs for Multiple Myeloma Revenue Market Share by Players (2018-2023)
- 3.2 Global Targeted Drugs for Multiple Myeloma Key Players Head office and Products Offered
- 3.3 Market Concentration Rate Analysis
 - 3.3.1 Competition Landscape Analysis
 - 3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
- 3.4 New Products and Potential Entrants
- 3.5 Mergers & Acquisitions, Expansion

4 TARGETED DRUGS FOR MULTIPLE MYELOMA BY REGIONS

- 4.1 Targeted Drugs for Multiple Myeloma Market Size by Regions (2018-2023)
- 4.2 Americas Targeted Drugs for Multiple Myeloma Market Size Growth (2018-2023)
- 4.3 APAC Targeted Drugs for Multiple Myeloma Market Size Growth (2018-2023)
- 4.4 Europe Targeted Drugs for Multiple Myeloma Market Size Growth (2018-2023)
- 4.5 Middle East & Africa Targeted Drugs for Multiple Myeloma Market Size Growth (2018-2023)

5 AMERICAS

- 5.1 Americas Targeted Drugs for Multiple Myeloma Market Size by Country (2018-2023)
- 5.2 Americas Targeted Drugs for Multiple Myeloma Market Size by Type (2018-2023)
- 5.3 Americas Targeted Drugs for Multiple Myeloma Market Size by Application (2018-2023)
- 5.4 United States
- 5.5 Canada
- 5.6 Mexico
- 5.7 Brazil

6 APAC

6.1 APAC Targeted Drugs for Multiple Myeloma Market Size by Region (2018-2023)



- 6.2 APAC Targeted Drugs for Multiple Myeloma Market Size by Type (2018-2023)
- 6.3 APAC Targeted Drugs for Multiple Myeloma Market Size by Application (2018-2023)
- 6.4 China
- 6.5 Japan
- 6.6 Korea
- 6.7 Southeast Asia
- 6.8 India
- 6.9 Australia

7 EUROPE

- 7.1 Europe Targeted Drugs for Multiple Myeloma by Country (2018-2023)
- 7.2 Europe Targeted Drugs for Multiple Myeloma Market Size by Type (2018-2023)
- 7.3 Europe Targeted Drugs for Multiple Myeloma Market Size by Application (2018-2023)
- 7.4 Germany
- 7.5 France
- 7.6 UK
- 7.7 Italy
- 7.8 Russia

8 MIDDLE EAST & AFRICA

- 8.1 Middle East & Africa Targeted Drugs for Multiple Myeloma by Region (2018-2023)
- 8.2 Middle East & Africa Targeted Drugs for Multiple Myeloma Market Size by Type (2018-2023)
- 8.3 Middle East & Africa Targeted Drugs for Multiple Myeloma Market Size by Application (2018-2023)
- 8.4 Egypt
- 8.5 South Africa
- 8.6 Israel
- 8.7 Turkey
- 8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

- 9.1 Market Drivers & Growth Opportunities
- 9.2 Market Challenges & Risks
- 9.3 Industry Trends



10 GLOBAL TARGETED DRUGS FOR MULTIPLE MYELOMA MARKET FORECAST

- 10.1 Global Targeted Drugs for Multiple Myeloma Forecast by Regions (2024-2029)
 - 10.1.1 Global Targeted Drugs for Multiple Myeloma Forecast by Regions (2024-2029)
 - 10.1.2 Americas Targeted Drugs for Multiple Myeloma Forecast
 - 10.1.3 APAC Targeted Drugs for Multiple Myeloma Forecast
 - 10.1.4 Europe Targeted Drugs for Multiple Myeloma Forecast
- 10.1.5 Middle East & Africa Targeted Drugs for Multiple Myeloma Forecast
- 10.2 Americas Targeted Drugs for Multiple Myeloma Forecast by Country (2024-2029)
 - 10.2.1 United States Targeted Drugs for Multiple Myeloma Market Forecast
 - 10.2.2 Canada Targeted Drugs for Multiple Myeloma Market Forecast
 - 10.2.3 Mexico Targeted Drugs for Multiple Myeloma Market Forecast
 - 10.2.4 Brazil Targeted Drugs for Multiple Myeloma Market Forecast
- 10.3 APAC Targeted Drugs for Multiple Myeloma Forecast by Region (2024-2029)
- 10.3.1 China Targeted Drugs for Multiple Myeloma Market Forecast
- 10.3.2 Japan Targeted Drugs for Multiple Myeloma Market Forecast
- 10.3.3 Korea Targeted Drugs for Multiple Myeloma Market Forecast
- 10.3.4 Southeast Asia Targeted Drugs for Multiple Myeloma Market Forecast
- 10.3.5 India Targeted Drugs for Multiple Myeloma Market Forecast
- 10.3.6 Australia Targeted Drugs for Multiple Myeloma Market Forecast
- 10.4 Europe Targeted Drugs for Multiple Myeloma Forecast by Country (2024-2029)
- 10.4.1 Germany Targeted Drugs for Multiple Myeloma Market Forecast
- 10.4.2 France Targeted Drugs for Multiple Myeloma Market Forecast
- 10.4.3 UK Targeted Drugs for Multiple Myeloma Market Forecast
- 10.4.4 Italy Targeted Drugs for Multiple Myeloma Market Forecast
- 10.4.5 Russia Targeted Drugs for Multiple Myeloma Market Forecast
- 10.5 Middle East & Africa Targeted Drugs for Multiple Myeloma Forecast by Region (2024-2029)
 - 10.5.1 Egypt Targeted Drugs for Multiple Myeloma Market Forecast
 - 10.5.2 South Africa Targeted Drugs for Multiple Myeloma Market Forecast
 - 10.5.3 Israel Targeted Drugs for Multiple Myeloma Market Forecast
 - 10.5.4 Turkey Targeted Drugs for Multiple Myeloma Market Forecast
 - 10.5.5 GCC Countries Targeted Drugs for Multiple Myeloma Market Forecast
- 10.6 Global Targeted Drugs for Multiple Myeloma Forecast by Type (2024-2029)
- 10.7 Global Targeted Drugs for Multiple Myeloma Forecast by Application (2024-2029)

11 KEY PLAYERS ANALYSIS



- 11.1 Celgene
 - 11.1.1 Celgene Company Information
 - 11.1.2 Celgene Targeted Drugs for Multiple Myeloma Product Offered
- 11.1.3 Celgene Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023)
 - 11.1.4 Celgene Main Business Overview
 - 11.1.5 Celgene Latest Developments
- 11.2 Exova
 - 11.2.1 Exova Company Information
 - 11.2.2 Exova Targeted Drugs for Multiple Myeloma Product Offered
- 11.2.3 Exova Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023)
 - 11.2.4 Exova Main Business Overview
 - 11.2.5 Exova Latest Developments
- 11.3 Natco Pharma
 - 11.3.1 Natco Pharma Company Information
 - 11.3.2 Natco Pharma Targeted Drugs for Multiple Myeloma Product Offered
- 11.3.3 Natco Pharma Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023)
 - 11.3.4 Natco Pharma Main Business Overview
 - 11.3.5 Natco Pharma Latest Developments
- 11.4 Intas Pharmaceuticals
 - 11.4.1 Intas Pharmaceuticals Company Information
 - 11.4.2 Intas Pharmaceuticals Targeted Drugs for Multiple Myeloma Product Offered
- 11.4.3 Intas Pharmaceuticals Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023)
 - 11.4.4 Intas Pharmaceuticals Main Business Overview
 - 11.4.5 Intas Pharmaceuticals Latest Developments
- 11.5 Indiabulls Pharmaceutical
 - 11.5.1 Indiabulls Pharmaceutical Company Information
- 11.5.2 Indiabulls Pharmaceutical Targeted Drugs for Multiple Myeloma Product Offered
- 11.5.3 Indiabulls Pharmaceutical Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023)
 - 11.5.4 Indiabulls Pharmaceutical Main Business Overview
 - 11.5.5 Indiabulls Pharmaceutical Latest Developments
- 11.6 Cipla
- 11.6.1 Cipla Company Information
- 11.6.2 Cipla Targeted Drugs for Multiple Myeloma Product Offered



- 11.6.3 Cipla Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023)
 - 11.6.4 Cipla Main Business Overview
 - 11.6.5 Cipla Latest Developments
- 11.7 Glenmark Pharmaceuticals
 - 11.7.1 Glenmark Pharmaceuticals Company Information
- 11.7.2 Glenmark Pharmaceuticals Targeted Drugs for Multiple Myeloma Product Offered
- 11.7.3 Glenmark Pharmaceuticals Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023)
 - 11.7.4 Glenmark Pharmaceuticals Main Business Overview
 - 11.7.5 Glenmark Pharmaceuticals Latest Developments
- 11.8 Dr Reddy's Laboratories
 - 11.8.1 Dr Reddy's Laboratories Company Information
- 11.8.2 Dr Reddy's Laboratories Targeted Drugs for Multiple Myeloma Product Offered
- 11.8.3 Dr Reddy's Laboratories Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023)
 - 11.8.4 Dr Reddy's Laboratories Main Business Overview
 - 11.8.5 Dr Reddy's Laboratories Latest Developments
- 11.9 Qilu Pharmaceutical
 - 11.9.1 Qilu Pharmaceutical Company Information
 - 11.9.2 Qilu Pharmaceutical Targeted Drugs for Multiple Myeloma Product Offered
- 11.9.3 Qilu Pharmaceutical Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023)
 - 11.9.4 Qilu Pharmaceutical Main Business Overview
 - 11.9.5 Qilu Pharmaceutical Latest Developments
- 11.10 Chia Tai-Tianqing
 - 11.10.1 Chia Tai-Tianqing Company Information
 - 11.10.2 Chia Tai-Tianqing Targeted Drugs for Multiple Myeloma Product Offered
- 11.10.3 Chia Tai-Tianqing Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023)
 - 11.10.4 Chia Tai-Tianqing Main Business Overview
 - 11.10.5 Chia Tai-Tianqing Latest Developments
- 11.11 Hanson Pharm
 - 11.11.1 Hanson Pharm Company Information
 - 11.11.2 Hanson Pharm Targeted Drugs for Multiple Myeloma Product Offered
- 11.11.3 Hanson Pharm Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023)
 - 11.11.4 Hanson Pharm Main Business Overview



- 11.11.5 Hanson Pharm Latest Developments
- 11.12 Meidakang Huakang Pharmaceutical
 - 11.12.1 Meidakang Huakang Pharmaceutical Company Information
- 11.12.2 Meidakang Huakang Pharmaceutical Targeted Drugs for Multiple Myeloma Product Offered
- 11.12.3 Meidakang Huakang Pharmaceutical Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023)
 - 11.12.4 Meidakang Huakang Pharmaceutical Main Business Overview
- 11.12.5 Meidakang Huakang Pharmaceutical Latest Developments
- 11.13 Shandong Kongfu Pharmaceutical
- 11.13.1 Shandong Kongfu Pharmaceutical Company Information
- 11.13.2 Shandong Kongfu Pharmaceutical Targeted Drugs for Multiple Myeloma Product Offered
- 11.13.3 Shandong Kongfu Pharmaceutical Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023)
 - 11.13.4 Shandong Kongfu Pharmaceutical Main Business Overview
- 11.13.5 Shandong Kongfu Pharmaceutical Latest Developments
- 11.14 J&J
 - 11.14.1 J&J Company Information
- 11.14.2 J&J Targeted Drugs for Multiple Myeloma Product Offered
- 11.14.3 J&J Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023)
 - 11.14.4 J&J Main Business Overview
 - 11.14.5 J&J Latest Developments
- 11.15 Takeda
 - 11.15.1 Takeda Company Information
 - 11.15.2 Takeda Targeted Drugs for Multiple Myeloma Product Offered
- 11.15.3 Takeda Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023)
 - 11.15.4 Takeda Main Business Overview
 - 11.15.5 Takeda Latest Developments
- 11.16 Amgen
 - 11.16.1 Amgen Company Information
 - 11.16.2 Amgen Targeted Drugs for Multiple Myeloma Product Offered
- 11.16.3 Amgen Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023)
 - 11.16.4 Amgen Main Business Overview
 - 11.16.5 Amgen Latest Developments
- 11.17 Bristol Myers Squibb



- 11.17.1 Bristol Myers Squibb Company Information
- 11.17.2 Bristol Myers Squibb Targeted Drugs for Multiple Myeloma Product Offered
- 11.17.3 Bristol Myers Squibb Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023)
 - 11.17.4 Bristol Myers Squibb Main Business Overview
 - 11.17.5 Bristol Myers Squibb Latest Developments
- 11.18 Abbvie
 - 11.18.1 Abbvie Company Information
 - 11.18.2 Abbvie Targeted Drugs for Multiple Myeloma Product Offered
- 11.18.3 Abbvie Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023)
 - 11.18.4 Abbvie Main Business Overview
 - 11.18.5 Abbvie Latest Developments
- 11.19 Seattle Genetics
 - 11.19.1 Seattle Genetics Company Information
 - 11.19.2 Seattle Genetics Targeted Drugs for Multiple Myeloma Product Offered
- 11.19.3 Seattle Genetics Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023)
 - 11.19.4 Seattle Genetics Main Business Overview
 - 11.19.5 Seattle Genetics Latest Developments
- 11.20 Karyopharm Therapeutics
 - 11.20.1 Karyopharm Therapeutics Company Information
- 11.20.2 Karyopharm Therapeutics Targeted Drugs for Multiple Myeloma Product Offered
- 11.20.3 Karyopharm Therapeutics Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023)
 - 11.20.4 Karyopharm Therapeutics Main Business Overview
 - 11.20.5 Karyopharm Therapeutics Latest Developments
- 11.21 PDL BioPharma
 - 11.21.1 PDL BioPharma Company Information
 - 11.21.2 PDL BioPharma Targeted Drugs for Multiple Myeloma Product Offered
- 11.21.3 PDL BioPharma Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023)
 - 11.21.4 PDL BioPharma Main Business Overview
 - 11.21.5 PDL BioPharma Latest Developments
- 11.22 Roche
 - 11.22.1 Roche Company Information
 - 11.22.2 Roche Targeted Drugs for Multiple Myeloma Product Offered
 - 11.22.3 Roche Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and



Market Share (2018-2023)

- 11.22.4 Roche Main Business Overview
- 11.22.5 Roche Latest Developments
- 11.23 Sumitomo
 - 11.23.1 Sumitomo Company Information
 - 11.23.2 Sumitomo Targeted Drugs for Multiple Myeloma Product Offered
- 11.23.3 Sumitomo Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023)
 - 11.23.4 Sumitomo Main Business Overview
 - 11.23.5 Sumitomo Latest Developments
- 11.24 Merck
 - 11.24.1 Merck Company Information
 - 11.24.2 Merck Targeted Drugs for Multiple Myeloma Product Offered
- 11.24.3 Merck Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023)
 - 11.24.4 Merck Main Business Overview
 - 11.24.5 Merck Latest Developments
- 11.25 Biogen
 - 11.25.1 Biogen Company Information
 - 11.25.2 Biogen Targeted Drugs for Multiple Myeloma Product Offered
- 11.25.3 Biogen Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023)
 - 11.25.4 Biogen Main Business Overview
 - 11.25.5 Biogen Latest Developments
- 11.26 Schering-Plough
 - 11.26.1 Schering-Plough Company Information
 - 11.26.2 Schering-Plough Targeted Drugs for Multiple Myeloma Product Offered
- 11.26.3 Schering-Plough Targeted Drugs for Multiple Myeloma Revenue, Gross
- Margin and Market Share (2018-2023)
 - 11.26.4 Schering-Plough Main Business Overview
 - 11.26.5 Schering-Plough Latest Developments
- 11.27 Glaxo
 - 11.27.1 Glaxo Company Information
 - 11.27.2 Glaxo Targeted Drugs for Multiple Myeloma Product Offered
- 11.27.3 Glaxo Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023)
 - 11.27.4 Glaxo Main Business Overview
 - 11.27.5 Glaxo Latest Developments
- 11.28 Chiron



- 11.28.1 Chiron Company Information
- 11.28.2 Chiron Targeted Drugs for Multiple Myeloma Product Offered
- 11.28.3 Chiron Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2018-2023)
 - 11.28.4 Chiron Main Business Overview
 - 11.28.5 Chiron Latest Developments

12 RESEARCH FINDINGS AND CONCLUSION



List Of Tables

LIST OF TABLES

- Table 1. Targeted Drugs for Multiple Myeloma Market Size CAGR by Region (2018 VS 2022 VS 2029) & (\$ Millions)
- Table 2. Major Players of Immunomodulator
- Table 3. Major Players of Proteasome Inhibitors
- Table 4. Major Players of Histone Deacetylase Inhibitors (HDACI)
- Table 5. Major Players of Monoclonal Antibody
- Table 6. Major Players of Other
- Table 7. Targeted Drugs for Multiple Myeloma Market Size CAGR by Type (2018 VS 2022 VS 2029) & (\$ Millions)
- Table 8. Global Targeted Drugs for Multiple Myeloma Market Size by Type (2018-2023) & (\$ Millions)
- Table 9. Global Targeted Drugs for Multiple Myeloma Market Size Market Share by Type (2018-2023)
- Table 10. Targeted Drugs for Multiple Myeloma Market Size CAGR by Application (2018 VS 2022 VS 2029) & (\$ Millions)
- Table 11. Global Targeted Drugs for Multiple Myeloma Market Size by Application (2018-2023) & (\$ Millions)
- Table 12. Global Targeted Drugs for Multiple Myeloma Market Size Market Share by Application (2018-2023)
- Table 13. Global Targeted Drugs for Multiple Myeloma Revenue by Players (2018-2023) & (\$ Millions)
- Table 14. Global Targeted Drugs for Multiple Myeloma Revenue Market Share by Player (2018-2023)
- Table 15. Targeted Drugs for Multiple Myeloma Key Players Head office and Products Offered
- Table 16. Targeted Drugs for Multiple Myeloma Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
- Table 17. New Products and Potential Entrants
- Table 18. Mergers & Acquisitions, Expansion
- Table 19. Global Targeted Drugs for Multiple Myeloma Market Size by Regions 2018-2023 & (\$ Millions)
- Table 20. Global Targeted Drugs for Multiple Myeloma Market Size Market Share by Regions (2018-2023)
- Table 21. Global Targeted Drugs for Multiple Myeloma Revenue by Country/Region (2018-2023) & (\$ millions)



- Table 22. Global Targeted Drugs for Multiple Myeloma Revenue Market Share by Country/Region (2018-2023)
- Table 23. Americas Targeted Drugs for Multiple Myeloma Market Size by Country (2018-2023) & (\$ Millions)
- Table 24. Americas Targeted Drugs for Multiple Myeloma Market Size Market Share by Country (2018-2023)
- Table 25. Americas Targeted Drugs for Multiple Myeloma Market Size by Type (2018-2023) & (\$ Millions)
- Table 26. Americas Targeted Drugs for Multiple Myeloma Market Size Market Share by Type (2018-2023)
- Table 27. Americas Targeted Drugs for Multiple Myeloma Market Size by Application (2018-2023) & (\$ Millions)
- Table 28. Americas Targeted Drugs for Multiple Myeloma Market Size Market Share by Application (2018-2023)
- Table 29. APAC Targeted Drugs for Multiple Myeloma Market Size by Region (2018-2023) & (\$ Millions)
- Table 30. APAC Targeted Drugs for Multiple Myeloma Market Size Market Share by Region (2018-2023)
- Table 31. APAC Targeted Drugs for Multiple Myeloma Market Size by Type (2018-2023) & (\$ Millions)
- Table 32. APAC Targeted Drugs for Multiple Myeloma Market Size Market Share by Type (2018-2023)
- Table 33. APAC Targeted Drugs for Multiple Myeloma Market Size by Application (2018-2023) & (\$ Millions)
- Table 34. APAC Targeted Drugs for Multiple Myeloma Market Size Market Share by Application (2018-2023)
- Table 35. Europe Targeted Drugs for Multiple Myeloma Market Size by Country (2018-2023) & (\$ Millions)
- Table 36. Europe Targeted Drugs for Multiple Myeloma Market Size Market Share by Country (2018-2023)
- Table 37. Europe Targeted Drugs for Multiple Myeloma Market Size by Type (2018-2023) & (\$ Millions)
- Table 38. Europe Targeted Drugs for Multiple Myeloma Market Size Market Share by Type (2018-2023)
- Table 39. Europe Targeted Drugs for Multiple Myeloma Market Size by Application (2018-2023) & (\$ Millions)
- Table 40. Europe Targeted Drugs for Multiple Myeloma Market Size Market Share by Application (2018-2023)
- Table 41. Middle East & Africa Targeted Drugs for Multiple Myeloma Market Size by



Region (2018-2023) & (\$ Millions)

Table 42. Middle East & Africa Targeted Drugs for Multiple Myeloma Market Size Market Share by Region (2018-2023)

Table 43. Middle East & Africa Targeted Drugs for Multiple Myeloma Market Size by Type (2018-2023) & (\$ Millions)

Table 44. Middle East & Africa Targeted Drugs for Multiple Myeloma Market Size Market Share by Type (2018-2023)

Table 45. Middle East & Africa Targeted Drugs for Multiple Myeloma Market Size by Application (2018-2023) & (\$ Millions)

Table 46. Middle East & Africa Targeted Drugs for Multiple Myeloma Market Size Market Share by Application (2018-2023)

Table 47. Key Market Drivers & Growth Opportunities of Targeted Drugs for Multiple Myeloma

Table 48. Key Market Challenges & Risks of Targeted Drugs for Multiple Myeloma

Table 49. Key Industry Trends of Targeted Drugs for Multiple Myeloma

Table 50. Global Targeted Drugs for Multiple Myeloma Market Size Forecast by Regions (2024-2029) & (\$ Millions)

Table 51. Global Targeted Drugs for Multiple Myeloma Market Size Market Share Forecast by Regions (2024-2029)

Table 52. Global Targeted Drugs for Multiple Myeloma Market Size Forecast by Type (2024-2029) & (\$ Millions)

Table 53. Global Targeted Drugs for Multiple Myeloma Market Size Forecast by Application (2024-2029) & (\$ Millions)

Table 54. Celgene Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors

Table 55. Celgene Targeted Drugs for Multiple Myeloma Product Offered

Table 56. Celgene Targeted Drugs for Multiple Myeloma Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 57. Celgene Main Business

Table 58. Celgene Latest Developments

Table 59. Exova Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors

Table 60. Exova Targeted Drugs for Multiple Myeloma Product Offered

Table 61. Exova Main Business

Table 62. Exova Targeted Drugs for Multiple Myeloma Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 63. Exova Latest Developments

Table 64. Natco Pharma Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors



- Table 65. Natco Pharma Targeted Drugs for Multiple Myeloma Product Offered
- Table 66. Natco Pharma Main Business
- Table 67. Natco Pharma Targeted Drugs for Multiple Myeloma Revenue (\$ million),
- Gross Margin and Market Share (2018-2023)
- Table 68. Natco Pharma Latest Developments
- Table 69. Intas Pharmaceuticals Details, Company Type, Targeted Drugs for Multiple
- Myeloma Area Served and Its Competitors
- Table 70. Intas Pharmaceuticals Targeted Drugs for Multiple Myeloma Product Offered
- Table 71. Intas Pharmaceuticals Main Business
- Table 72. Intas Pharmaceuticals Targeted Drugs for Multiple Myeloma Revenue (\$
- million), Gross Margin and Market Share (2018-2023)
- Table 73. Intas Pharmaceuticals Latest Developments
- Table 74. Indiabulls Pharmaceutical Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
- Table 75. Indiabulls Pharmaceutical Targeted Drugs for Multiple Myeloma Product Offered
- Table 76. Indiabulls Pharmaceutical Main Business
- Table 77. Indiabulls Pharmaceutical Targeted Drugs for Multiple Myeloma Revenue (\$ million), Gross Margin and Market Share (2018-2023)
- Table 78. Indiabulls Pharmaceutical Latest Developments
- Table 79. Cipla Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
- Table 80. Cipla Targeted Drugs for Multiple Myeloma Product Offered
- Table 81. Cipla Main Business
- Table 82. Cipla Targeted Drugs for Multiple Myeloma Revenue (\$ million), Gross Margin and Market Share (2018-2023)
- Table 83. Cipla Latest Developments
- Table 84. Glenmark Pharmaceuticals Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
- Table 85. Glenmark Pharmaceuticals Targeted Drugs for Multiple Myeloma Product Offered
- Table 86. Glenmark Pharmaceuticals Main Business
- Table 87. Glenmark Pharmaceuticals Targeted Drugs for Multiple Myeloma Revenue (\$ million), Gross Margin and Market Share (2018-2023)
- Table 88. Glenmark Pharmaceuticals Latest Developments
- Table 89. Dr Reddy's Laboratories Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
- Table 90. Dr Reddy's Laboratories Targeted Drugs for Multiple Myeloma Product Offered



Table 91. Dr Reddy's Laboratories Main Business

Table 92. Dr Reddy's Laboratories Targeted Drugs for Multiple Myeloma Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 93. Dr Reddy's Laboratories Latest Developments

Table 94. Qilu Pharmaceutical Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors

Table 95. Qilu Pharmaceutical Targeted Drugs for Multiple Myeloma Product Offered

Table 96. Qilu Pharmaceutical Main Business

Table 97. Qilu Pharmaceutical Targeted Drugs for Multiple Myeloma Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 98. Qilu Pharmaceutical Latest Developments

Table 99. Chia Tai-Tianqing Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors

Table 100. Chia Tai-Tianqing Targeted Drugs for Multiple Myeloma Product Offered

Table 101. Chia Tai-Tianqing Main Business

Table 102. Chia Tai-Tianqing Targeted Drugs for Multiple Myeloma Revenue (\$ million),

Gross Margin and Market Share (2018-2023)

Table 103. Chia Tai-Tianqing Latest Developments

Table 104. Hanson Pharm Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors

Table 105. Hanson Pharm Targeted Drugs for Multiple Myeloma Product Offered

Table 106. Hanson Pharm Targeted Drugs for Multiple Myeloma Revenue (\$ million),

Gross Margin and Market Share (2018-2023)

Table 107. Hanson Pharm Main Business

Table 108. Hanson Pharm Latest Developments

Table 109. Meidakang Huakang Pharmaceutical Details, Company Type, Targeted

Drugs for Multiple Myeloma Area Served and Its Competitors

Table 110. Meidakang Huakang Pharmaceutical Targeted Drugs for Multiple Myeloma Product Offered

Table 111. Meidakang Huakang Pharmaceutical Main Business

Table 112. Meidakang Huakang Pharmaceutical Targeted Drugs for Multiple Myeloma Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 113. Meidakang Huakang Pharmaceutical Latest Developments

Table 114. Shandong Kongfu Pharmaceutical Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors

Table 115. Shandong Kongfu Pharmaceutical Targeted Drugs for Multiple Myeloma Product Offered

Table 116. Shandong Kongfu Pharmaceutical Main Business

Table 117. Shandong Kongfu Pharmaceutical Targeted Drugs for Multiple Myeloma



Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 118. Shandong Kongfu Pharmaceutical Latest Developments

Table 119. J&J Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors

Table 120. J&J Targeted Drugs for Multiple Myeloma Product Offered

Table 121. J&J Main Business

Table 122. J&J Targeted Drugs for Multiple Myeloma Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 123. J&J Latest Developments

Table 124. Takeda Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors

Table 125. Takeda Targeted Drugs for Multiple Myeloma Product Offered

Table 126. Takeda Main Business

Table 127. Takeda Targeted Drugs for Multiple Myeloma Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 128. Takeda Latest Developments

Table 129. Amgen Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors

Table 130. Amgen Targeted Drugs for Multiple Myeloma Product Offered

Table 131. Amgen Main Business

Table 132. Amgen Targeted Drugs for Multiple Myeloma Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 133. Amgen Latest Developments

Table 134. Bristol Myers Squibb Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors

Table 135. Bristol Myers Squibb Targeted Drugs for Multiple Myeloma Product Offered

Table 136. Bristol Myers Squibb Main Business

Table 137. Bristol Myers Squibb Targeted Drugs for Multiple Myeloma Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 138. Bristol Myers Squibb Latest Developments

Table 139. Abbvie Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors

Table 140. Abbvie Targeted Drugs for Multiple Myeloma Product Offered

Table 141. Abbvie Main Business

Table 142. Abbvie Targeted Drugs for Multiple Myeloma Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 143. Abbvie Latest Developments

Table 144. Seattle Genetics Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors



- Table 145. Seattle Genetics Targeted Drugs for Multiple Myeloma Product Offered
- Table 146. Seattle Genetics Main Business
- Table 147. Seattle Genetics Targeted Drugs for Multiple Myeloma Revenue (\$ million),

Gross Margin and Market Share (2018-2023)

- Table 148. Seattle Genetics Latest Developments
- Table 149. Karyopharm Therapeutics Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
- Table 150. Karyopharm Therapeutics Targeted Drugs for Multiple Myeloma Product Offered
- Table 151. Karyopharm Therapeutics Main Business
- Table 152. Karyopharm Therapeutics Targeted Drugs for Multiple Myeloma Revenue (\$ million), Gross Margin and Market Share (2018-2023)
- Table 153. Karyopharm Therapeutics Latest Developments
- Table 154. PDL BioPharma Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
- Table 155. PDL BioPharma Targeted Drugs for Multiple Myeloma Product Offered
- Table 156. PDL BioPharma Targeted Drugs for Multiple Myeloma Revenue (\$ million),

Gross Margin and Market Share (2018-2023)

- Table 157. PDL BioPharma Main Business
- Table 158. PDL BioPharma Latest Developments
- Table 159. Roche Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
- Table 160. Roche Targeted Drugs for Multiple Myeloma Product Offered
- Table 161. Roche Main Business
- Table 162. Roche Targeted Drugs for Multiple Myeloma Revenue (\$ million), Gross Margin and Market Share (2018-2023)
- Table 163. Roche Latest Developments
- Table 164. Sumitomo Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
- Table 165. Sumitomo Targeted Drugs for Multiple Myeloma Product Offered
- Table 166. Sumitomo Main Business
- Table 167. Sumitomo Targeted Drugs for Multiple Myeloma Revenue (\$ million), Gross Margin and Market Share (2018-2023)
- Table 168. Sumitomo Latest Developments
- Table 169. Merck Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors
- Table 170. Merck Targeted Drugs for Multiple Myeloma Product Offered
- Table 171. Merck Main Business
- Table 172. Merck Targeted Drugs for Multiple Myeloma Revenue (\$ million), Gross



Margin and Market Share (2018-2023)

Table 173. Merck Latest Developments

Table 174. Biogen Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors

Table 175. Biogen Targeted Drugs for Multiple Myeloma Product Offered

Table 176. Biogen Main Business

Table 177. Biogen Targeted Drugs for Multiple Myeloma Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 178. Biogen Latest Developments

Table 179. Schering-Plough Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors

Table 180. Schering-Plough Targeted Drugs for Multiple Myeloma Product Offered

Table 181. Schering-Plough Main Business

Table 182. Schering-Plough Targeted Drugs for Multiple Myeloma Revenue (\$ million),

Gross Margin and Market Share (2018-2023)

Table 183. Schering-Plough Latest Developments

Table 184. Glaxo Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors

Table 185. Glaxo Targeted Drugs for Multiple Myeloma Product Offered

Table 186. Glaxo Main Business

Table 187. Glaxo Targeted Drugs for Multiple Myeloma Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 188. Glaxo Latest Developments

Table 189. Chiron Details, Company Type, Targeted Drugs for Multiple Myeloma Area Served and Its Competitors

Table 190. Chiron Targeted Drugs for Multiple Myeloma Product Offered

Table 191. Chiron Main Business

Table 192. Chiron Targeted Drugs for Multiple Myeloma Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 193. Chiron Latest Developments



List Of Figures

LIST OF FIGURES

- Figure 1. Targeted Drugs for Multiple Myeloma Report Years Considered
- Figure 2. Research Objectives
- Figure 3. Research Methodology
- Figure 4. Research Process and Data Source
- Figure 5. Global Targeted Drugs for Multiple Myeloma Market Size Growth Rate 2018-2029 (\$ Millions)
- Figure 6. Targeted Drugs for Multiple Myeloma Sales by Geographic Region (2018, 2022 & 2029) & (\$ millions)
- Figure 7. Targeted Drugs for Multiple Myeloma Sales Market Share by Country/Region (2022)
- Figure 8. Targeted Drugs for Multiple Myeloma Sales Market Share by Country/Region (2018, 2022 & 2029)
- Figure 9. Global Targeted Drugs for Multiple Myeloma Market Size Market Share by Type in 2022
- Figure 10. Targeted Drugs for Multiple Myeloma in Hospital
- Figure 11. Global Targeted Drugs for Multiple Myeloma Market: Hospital (2018-2023) & (\$ Millions)
- Figure 12. Targeted Drugs for Multiple Myeloma in Drug Center
- Figure 13. Global Targeted Drugs for Multiple Myeloma Market: Drug Center (2018-2023) & (\$ Millions)
- Figure 14. Targeted Drugs for Multiple Myeloma in Clinic
- Figure 15. Global Targeted Drugs for Multiple Myeloma Market: Clinic (2018-2023) & (\$ Millions)
- Figure 16. Targeted Drugs for Multiple Myeloma in Other
- Figure 17. Global Targeted Drugs for Multiple Myeloma Market: Other (2018-2023) & (\$ Millions)
- Figure 18. Global Targeted Drugs for Multiple Myeloma Market Size Market Share by Application in 2022
- Figure 19. Global Targeted Drugs for Multiple Myeloma Revenue Market Share by Player in 2022
- Figure 20. Global Targeted Drugs for Multiple Myeloma Market Size Market Share by Regions (2018-2023)
- Figure 21. Americas Targeted Drugs for Multiple Myeloma Market Size 2018-2023 (\$ Millions)
- Figure 22. APAC Targeted Drugs for Multiple Myeloma Market Size 2018-2023 (\$



Millions)

Figure 23. Europe Targeted Drugs for Multiple Myeloma Market Size 2018-2023 (\$ Millions)

Figure 24. Middle East & Africa Targeted Drugs for Multiple Myeloma Market Size 2018-2023 (\$ Millions)

Figure 25. Americas Targeted Drugs for Multiple Myeloma Value Market Share by Country in 2022

Figure 26. United States Targeted Drugs for Multiple Myeloma Market Size Growth 2018-2023 (\$ Millions)

Figure 27. Canada Targeted Drugs for Multiple Myeloma Market Size Growth 2018-2023 (\$ Millions)

Figure 28. Mexico Targeted Drugs for Multiple Myeloma Market Size Growth 2018-2023 (\$ Millions)

Figure 29. Brazil Targeted Drugs for Multiple Myeloma Market Size Growth 2018-2023 (\$ Millions)

Figure 30. APAC Targeted Drugs for Multiple Myeloma Market Size Market Share by Region in 2022

Figure 31. APAC Targeted Drugs for Multiple Myeloma Market Size Market Share by Type in 2022

Figure 32. APAC Targeted Drugs for Multiple Myeloma Market Size Market Share by Application in 2022

Figure 33. China Targeted Drugs for Multiple Myeloma Market Size Growth 2018-2023 (\$ Millions)

Figure 34. Japan Targeted Drugs for Multiple Myeloma Market Size Growth 2018-2023 (\$ Millions)

Figure 35. Korea Targeted Drugs for Multiple Myeloma Market Size Growth 2018-2023 (\$ Millions)

Figure 36. Southeast Asia Targeted Drugs for Multiple Myeloma Market Size Growth 2018-2023 (\$ Millions)

Figure 37. India Targeted Drugs for Multiple Myeloma Market Size Growth 2018-2023 (\$ Millions)

Figure 38. Australia Targeted Drugs for Multiple Myeloma Market Size Growth 2018-2023 (\$ Millions)

Figure 39. Europe Targeted Drugs for Multiple Myeloma Market Size Market Share by Country in 2022

Figure 40. Europe Targeted Drugs for Multiple Myeloma Market Size Market Share by Type (2018-2023)

Figure 41. Europe Targeted Drugs for Multiple Myeloma Market Size Market Share by Application (2018-2023)



Figure 42. Germany Targeted Drugs for Multiple Myeloma Market Size Growth 2018-2023 (\$ Millions)

Figure 43. France Targeted Drugs for Multiple Myeloma Market Size Growth 2018-2023 (\$ Millions)

Figure 44. UK Targeted Drugs for Multiple Myeloma Market Size Growth 2018-2023 (\$ Millions)

Figure 45. Italy Targeted Drugs for Multiple Myeloma Market Size Growth 2018-2023 (\$ Millions)

Figure 46. Russia Targeted Drugs for Multiple Myeloma Market Size Growth 2018-2023 (\$ Millions)

Figure 47. Middle East & Africa Targeted Drugs for Multiple Myeloma Market Size Market Share by Region (2018-2023)

Figure 48. Middle East & Africa Targeted Drugs for Multiple Myeloma Market Size Market Share by Type (2018-2023)

Figure 49. Middle East & Africa Targeted Drugs for Multiple Myeloma Market Size Market Share by Application (2018-2023)

Figure 50. Egypt Targeted Drugs for Multiple Myeloma Market Size Growth 2018-2023 (\$ Millions)

Figure 51. South Africa Targeted Drugs for Multiple Myeloma Market Size Growth 2018-2023 (\$ Millions)

Figure 52. Israel Targeted Drugs for Multiple Myeloma Market Size Growth 2018-2023 (\$ Millions)

Figure 53. Turkey Targeted Drugs for Multiple Myeloma Market Size Growth 2018-2023 (\$ Millions)

Figure 54. GCC Country Targeted Drugs for Multiple Myeloma Market Size Growth 2018-2023 (\$ Millions)

Figure 55. Americas Targeted Drugs for Multiple Myeloma Market Size 2024-2029 (\$ Millions)

Figure 56. APAC Targeted Drugs for Multiple Myeloma Market Size 2024-2029 (\$ Millions)

Figure 57. Europe Targeted Drugs for Multiple Myeloma Market Size 2024-2029 (\$ Millions)

Figure 58. Middle East & Africa Targeted Drugs for Multiple Myeloma Market Size 2024-2029 (\$ Millions)

Figure 59. United States Targeted Drugs for Multiple Myeloma Market Size 2024-2029 (\$ Millions)

Figure 60. Canada Targeted Drugs for Multiple Myeloma Market Size 2024-2029 (\$ Millions)

Figure 61. Mexico Targeted Drugs for Multiple Myeloma Market Size 2024-2029 (\$



- Millions)
- Figure 62. Brazil Targeted Drugs for Multiple Myeloma Market Size 2024-2029 (\$ Millions)
- Figure 63. China Targeted Drugs for Multiple Myeloma Market Size 2024-2029 (\$ Millions)
- Figure 64. Japan Targeted Drugs for Multiple Myeloma Market Size 2024-2029 (\$ Millions)
- Figure 65. Korea Targeted Drugs for Multiple Myeloma Market Size 2024-2029 (\$ Millions)
- Figure 66. Southeast Asia Targeted Drugs for Multiple Myeloma Market Size 2024-2029 (\$ Millions)
- Figure 67. India Targeted Drugs for Multiple Myeloma Market Size 2024-2029 (\$ Millions)
- Figure 68. Australia Targeted Drugs for Multiple Myeloma Market Size 2024-2029 (\$ Millions)
- Figure 69. Germany Targeted Drugs for Multiple Myeloma Market Size 2024-2029 (\$ Millions)
- Figure 70. France Targeted Drugs for Multiple Myeloma Market Size 2024-2029 (\$ Millions)
- Figure 71. UK Targeted Drugs for Multiple Myeloma Market Size 2024-2029 (\$ Millions)
- Figure 72. Italy Targeted Drugs for Multiple Myeloma Market Size 2024-2029 (\$ Millions)
- Figure 73. Russia Targeted Drugs for Multiple Myeloma Market Size 2024-2029 (\$ Millions)
- Figure 74. Spain Targeted Drugs for Multiple Myeloma Market Size 2024-2029 (\$ Millions)
- Figure 75. Egypt Targeted Drugs for Multiple Myeloma Market Size 2024-2029 (\$ Millions)
- Figure 76. South Africa Targeted Drugs for Multiple Myeloma Market Size 2024-2029 (\$ Millions)
- Figure 77. Israel Targeted Drugs for Multiple Myeloma Market Size 2024-2029 (\$ Millions)
- Figure 78. Turkey Targeted Drugs for Multiple Myeloma Market Size 2024-2029 (\$ Millions)
- Figure 79. GCC Countries Targeted Drugs for Multiple Myeloma Market Size 2024-2029 (\$ Millions)
- Figure 80. Global Targeted Drugs for Multiple Myeloma Market Size Market Share Forecast by Type (2024-2029)
- Figure 81. Global Targeted Drugs for Multiple Myeloma Market Size Market Share



Forecast by Application (2024-2029)



I would like to order

Product name: Global Targeted Drugs for Multiple Myeloma Market Growth (Status and Outlook)

2023-2029

Product link: https://marketpublishers.com/r/G444DD763F1EN.html

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

First name:

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/G444DD763F1EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970



